RNAC
Price:
$9.51
Market Cap:
$279.42M
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the advancement and discovery of nanoparticle-based immunomodulatory drugs. These innovative therapeutics are designed to both treat and prevent a variety of human ailments. The company's leading gene therapy initiative, SEL-302, is currently undergoing Phase I clinical trials, with the goal of improving the efficacy of treatment for methylmalonic acidemia. Its product pipeline also features biologic therapies, including SEL-212, which is now in Phase III clinical trials for the management of chronic refractory gout. Furthermore, Selecta is developing candidate therapies specifically aimed at various I...[Read more]
Industry
Biotechnology
IPO Date
2016-06-22
Stock Exchange
NASDAQ
Ticker
RNAC
According to Cartesian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.64. This represents a change of -882.84% compared to the average of 0.21 of the last 4 quarters.
The mean historical PE Ratio of Cartesian Therapeutics, Inc. over the last ten years is -2.89. The current -1.64 PE Ratio has changed 5.57% with respect to the historical average. Over the past ten years (40 quarters), RNAC's PE Ratio was at its highest in in the June 2021 quarter at 21.66. The PE Ratio was at its lowest in in the December 2024 quarter at -11.31.
Average
-2.89
Median
-2.09
Minimum
-12.09
Maximum
3.85
Discovering the peaks and valleys of Cartesian Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.20%
Maximum Annual PE Ratio = 3.85
Minimum Annual Increase = -131.87%
Minimum Annual PE Ratio = -12.09
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -1.44 | -76.02% |
| 2024 | -5.99 | 1.20% |
| 2023 | -0.46 | -112.01% |
| 2022 | 3.85 | -131.87% |
| 2021 | -12.09 | 225.91% |
| 2020 | -3.71 | 127.32% |
| 2019 | -1.63 | 114.86% |
| 2018 | -0.76 | -70.28% |
| 2017 | -2.56 | -38.28% |
| 2016 | -4.14 | -30.55% |
The current PE Ratio of Cartesian Therapeutics, Inc. (RNAC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.63
5-year avg
-3.23
10-year avg
-2.89
Cartesian Therapeutics, Inc.’s PE Ratio is greater than Eupraxia Pharmaceuticals Inc. (-8.12), greater than Inventiva S.A. (-6.15), greater than Nautilus Biotechnology, Inc. (-4.97), greater than Orchestra BioMed Holdings, Inc. (-2.88), greater than MediWound Ltd. (-7.01), less than Aardvark Therapeutics, Inc. Common Stock (-1.22), greater than Fennec Pharmaceuticals Inc. (-36.89), greater than Avalo Therapeutics, Inc. (-3.50), greater than Neonc Technologies Holdings, Inc. (-2.86), greater than Genfit S.A. (-5.37),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.12 | $202.22M | |
| -6.15 | $200.13M | |
| -4.97 | $284.66M | |
| -2.88 | $245.51M | |
| -7.01 | $154.46M | |
| -1.22 | $85.08M | |
| -36.89 | $257.22M | |
| -3.50 | $166.70M | |
| -2.86 | $94.98M | |
| -5.37 | $445.68M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cartesian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cartesian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cartesian Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cartesian Therapeutics, Inc. (RNAC)?
What is the highest PE Ratio for Cartesian Therapeutics, Inc. (RNAC)?
What is the 3-year average PE Ratio for Cartesian Therapeutics, Inc. (RNAC)?
What is the 5-year average PE Ratio for Cartesian Therapeutics, Inc. (RNAC)?
How does the current PE Ratio for Cartesian Therapeutics, Inc. (RNAC) compare to its historical average?